BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care. 2018;41:1801-1808. [PMID: 29895557 DOI: 10.2337/dc18-0165] [Cited by in Crossref: 267] [Cited by in F6Publishing: 286] [Article Influence: 53.4] [Reference Citation Analysis]
Number Citing Articles
1 Sato M, Akamatsu M, Shima T, Ikegami T, Yanase M, Mikami S, Imamura J, Nakatsuka T, Tateishi R, Yamauchi N, Ushiku T, Okanoue T, Fujishiro M, Hida E, Koike K. Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial. Am J Gastroenterol 2023. [PMID: 36656974 DOI: 10.14309/ajg.0000000000002143] [Reference Citation Analysis]
2 Yang Z, Tian R, Zhang X, Cai J, She Z, Li H. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med 2023;9. [DOI: 10.3389/fcvm.2022.1120085] [Reference Citation Analysis]
3 Zou CY, Sun Y, Liang J. Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis(,). Clin Res Hepatol Gastroenterol 2023;47:102053. [PMID: 36403941 DOI: 10.1016/j.clinre.2022.102053] [Reference Citation Analysis]
4 Senn J, Fischli S. Medical therapy. Visceral and Ectopic Fat 2023. [DOI: 10.1016/b978-0-12-822186-0.00014-6] [Reference Citation Analysis]
5 Yao H, Wang Y, Zhang X, Li P, Shang L, Chen X, Zeng J. Targeting peroxisomal fatty acid oxidation improves hepatic steatosis and insulin resistance in obese mice. J Biol Chem 2022;:102845. [PMID: 36586435 DOI: 10.1016/j.jbc.2022.102845] [Reference Citation Analysis]
6 Chen JYS, Chua D, Lim CO, Ho WX, Tan NS. Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials. Int J Mol Sci 2022;24. [PMID: 36613602 DOI: 10.3390/ijms24010158] [Reference Citation Analysis]
7 Radlinger B, Ress C, Folie S, Salzmann K, Lechuga A, Weiss B, Salvenmoser W, Graber M, Hirsch J, Holfeld J, Kremser C, Moser P, Staudacher G, Jelenik T, Roden M, Tilg H, Kaser S. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia 2022. [DOI: 10.1007/s00125-022-05851-x] [Reference Citation Analysis]
8 Oura K, Morishita A, Tani J, Masaki T. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma. J Hepatocell Carcinoma 2022;9:1279-98. [PMID: 36545268 DOI: 10.2147/JHC.S392051] [Reference Citation Analysis]
9 Elhini SH, Wahsh EA, Elberry AA, El Ameen NF, Abdelfadil Saedii A, Refaie SM, Elsayed AA, Rabea HM. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals (Basel) 2022;15. [PMID: 36558967 DOI: 10.3390/ph15121516] [Reference Citation Analysis]
10 Kim J, Han K, Kim B, Baek KH, Song KH, Kim MK, Kwon HS. Sodium-glucose cotransporter 2 inhibitors for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A nationwide propensity-score matched cohort study. Diabetes Res Clin Pract 2022;194:110187. [PMID: 36442545 DOI: 10.1016/j.diabres.2022.110187] [Reference Citation Analysis]
11 Rojano A, Sena E, Manzano-nuñez R, Pericàs JM, Ciudin A. NAFLD as the metabolic hallmark of obesity. Intern Emerg Med 2022. [DOI: 10.1007/s11739-022-03139-x] [Reference Citation Analysis]
12 Ge M, Molina J, Kim J, Mallela SK, Ahmad A, Santos JV, Al-ali H, Mitrofanova A, Sharma K, Fontanesi F, Merscher S, Fornoni A. Empagliflozin reduces renal lipotoxicity in experimental Alport syndrome.. [DOI: 10.1101/2022.10.04.510832] [Reference Citation Analysis]
13 Hsu SJ, Huang HC, Pun CK, Chang CC, Chuang CL, Huang YH, Hou MC, Lee FY. Sodium-Glucose Cotransporter-2 Inhibition Exacerbates Hepatic Encephalopathy in Biliary Cirrhotic Rats. J Pharmacol Exp Ther 2022;383:25-31. [PMID: 35926870 DOI: 10.1124/jpet.122.001289] [Reference Citation Analysis]
14 Sakuma T, Nakamura M, Chiba T, Iwanaga T, Kan M, Kojima R, Ao J, Ma Y, Unozawa H, Fujita N, Kanayama K, Kanzaki H, Koroki K, Kobayashi K, Nakagawa R, Kanogawa N, Kiyono S, Kondo T, Saito T, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kishimoto T, Kato N. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis. Lab Invest 2022;102:1150-1157. [DOI: 10.1038/s41374-022-00807-6] [Reference Citation Analysis]
15 Mordi IR, Lang CC. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors. Heart Failure Clinics 2022;18:529-538. [DOI: 10.1016/j.hfc.2022.03.004] [Reference Citation Analysis]
16 Salah HM, Fudim M. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease. Heart Failure Clinics 2022;18:625-634. [DOI: 10.1016/j.hfc.2022.03.011] [Reference Citation Analysis]
17 Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [DOI: 10.4254/wjh.v14.i9.1718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Abebe G, Ayanaw D, Ayelgn Mengstie T, Dessie G, Malik T. Assessment of fatty liver and its correlation with glycemic control in patients with type 2 diabetes mellitus attending Dessie Comprehensive Specialized Hospital, Northeast Ethiopia. SAGE Open Med 2022;10:20503121221124762. [PMID: 36161212 DOI: 10.1177/20503121221124762] [Reference Citation Analysis]
19 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
20 Yang X, Yuan F, Wu N, Ren D, Liu L, Bi Y, Ji L, Han K, Feng M, Su K, Yang F, Wu X, Lu Q, Yue S, Jiang F, Wang R, He G, Liu B, Li X, Shi Y. Correlation of PCSK1 with nonalcoholic fatty liver disease in a Han Chinese population: a case-control observational study. Journal of Bio-X Research 2022;Publish Ahead of Print. [DOI: 10.1097/jbr.0000000000000124] [Reference Citation Analysis]
21 Egers M, Hynes M. Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care 2022;7:216-224. [DOI: 10.12968/jokc.2022.7.5.216] [Reference Citation Analysis]
22 Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun 2022;6:3073-82. [PMID: 36039537 DOI: 10.1002/hep4.2069] [Reference Citation Analysis]
23 Bañares J, Manzano-nuñez R, Prió A, Rivera-esteban J, Camps-relats L, Villarejo A, Ruiz-ortega L, Pons M, Ciudin A, Salcedo MT, Vargas V, Genescà J, Pericàs JM. Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study. Front Endocrinol 2022;13:945626. [DOI: 10.3389/fendo.2022.945626] [Reference Citation Analysis]
24 Arredouani A. Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. Lifestyle-Related Diseases and Metabolic Syndrome [Working Title] 2022. [DOI: 10.5772/intechopen.106445] [Reference Citation Analysis]
25 García-Compeán D, Kumar R, Cueto-Aguilera ÁND, Maldonado-Garza HJ, Villarreal-Pérez JZ. Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents. Ann Hepatol 2022;:100751. [PMID: 36002119 DOI: 10.1016/j.aohep.2022.100751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Althobaiti FM, Alsanosi SM, Falemban AH, Alzahrani AR, Fataha SA, Salih SO, Alrumaih AM, Alotaibi KN, Althobaiti HM, Al-ghamdi SS, Ayoub N. Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study. JCM 2022;11:4769. [DOI: 10.3390/jcm11164769] [Reference Citation Analysis]
27 Xu X, Poulsen KL, Wu L, Liu S, Miyata T, Song Q, Wei Q, Zhao C, Lin C, Yang J. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 2022;7:287. [PMID: 35963848 DOI: 10.1038/s41392-022-01119-3] [Reference Citation Analysis]
28 Bae J, Lee JY, Shin E, Lee M, Lee YH, Lee BW, Kang ES, Cha BS. The effects of the voglibose on non-alcoholic fatty liver disease in mice model. Sci Rep 2022;12:13595. [PMID: 35948569 DOI: 10.1038/s41598-022-15550-7] [Reference Citation Analysis]
29 Ahmed SH, Moeed A, Waqar E, Rizwan S, Hasnain N, Qamar MA, Fatima K, Khan Minhas AM. Efficacy of sodium-glucose co-transporter 2 inhibitors in treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Obesity Medicine 2022;33:100437. [DOI: 10.1016/j.obmed.2022.100437] [Reference Citation Analysis]
30 Kuchay MS, Misra A. Sodium-glucose cotransporter-2 inhibitors as first-line pharmacological therapy for type 2 diabetes? Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2022;16:102580. [DOI: 10.1016/j.dsx.2022.102580] [Reference Citation Analysis]
31 Doustmohammadian A, Nezhadisalami A, Safarnezhad Tameshke F, Motamed N, Maadi M, Farahmand M, Sohrabi M, Clark CCT, Ajdarkosh H, Faraji AH, Nikkhah M, Sobhrakhshankhah E, Ebrahimi R, Zamani F. A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes. Front Med 2022;9. [DOI: 10.3389/fmed.2022.937554] [Reference Citation Analysis]
32 Wang Z, Ye M, Zhang XJ, Zhang P, Cai J, Li H, She ZG. Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. Atherosclerosis 2022;355:30-44. [PMID: 35872444 DOI: 10.1016/j.atherosclerosis.2022.07.010] [Reference Citation Analysis]
33 Bellanti F, Lo Buglio A, Dobrakowski M, Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G, Vendemiale G. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease. World J Gastroenterol 2022; 28(26): 3243-3257 [DOI: 10.3748/wjg.v28.i26.3243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Yan H, Huang C, Shen X, Li J, Zhou S, Li W. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis. Front Endocrinol 2022;13:923606. [DOI: 10.3389/fendo.2022.923606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kim K. Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents. J Korean Diabetes 2022;23:83-88. [DOI: 10.4093/jkd.2022.23.2.83] [Reference Citation Analysis]
36 Palma R, Pronio A, Romeo M, Scognamiglio F, Ventriglia L, Ormando VM, Lamazza A, Pontone S, Federico A, Dallio M. The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. JCM 2022;11:3649. [DOI: 10.3390/jcm11133649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
37 Bea S, Jeong HE, Park S, Yu OHY, Chang Y, Cho J, Sinn DH, Cho YM, Shin JY. Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study. Gut 2022:gutjnl-2022-327504. [PMID: 35725292 DOI: 10.1136/gutjnl-2022-327504] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, Ravussin E, Charatcharoenwitthaya P, Cheng PN, Katchman H, Klein S, Ben-Ari Z, Mendonza AE, Zhang Y, Martic M, Ma S, Kao S, Tanner S, Pachori A, Badman MK, He Y, Ukomadu C, Sicard E. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med 2022. [PMID: 35725922 DOI: 10.1038/s41591-022-01861-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, Ferrer R, Pericàs JM, Ciudin A. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med 2022;11:3286. [PMID: 35743358 DOI: 10.3390/jcm11123286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Rhee EJ. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Endocrinol Metab (Seoul) 2022;37:415-29. [PMID: 35798548 DOI: 10.3803/EnM.2022.304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Moon JS, Hong JH, Jung YJ, Ferrannini E, Nauck MA, Lim S. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2022;33:424-42. [PMID: 35491295 DOI: 10.1016/j.tem.2022.03.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022;21:83. [PMID: 35614469 DOI: 10.1186/s12933-022-01512-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Chavez E, Rodriguez J, Drexler Y, Fornoni A. Novel Therapies for Alport Syndrome. Front Med (Lausanne) 2022;9:848389. [PMID: 35547199 DOI: 10.3389/fmed.2022.848389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Miyazaki R, Miyagi K. Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases. BMC Nephrol 2022;23:168. [PMID: 35501824 DOI: 10.1186/s12882-022-02793-9] [Reference Citation Analysis]
45 Polyzos SA, Goulis DG, Giouleme O, Germanidis GS, Goulas A. Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease. Curr Obes Rep 2022. [PMID: 35501557 DOI: 10.1007/s13679-022-00474-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Chan WK, Tan SS, Chan SP, Lee YY, Tee HP, Mahadeva S, Goh KL, Ramli AS, Mustapha F, Kosai NR, Raja Ali RA. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol 2022;37:795-811. [PMID: 35080048 DOI: 10.1111/jgh.15787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Chadha M, Das AK, Deb P, Gangopadhyay KK, Joshi S, Kesavadev J, Kovil R, Kumar S, Misra A, Mohan V. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Ther 2022;13:1097-114. [PMID: 35334083 DOI: 10.1007/s13300-022-01219-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Park J, Kim G, Kim B, Han K, Kwon SY, Park SH, Lee Y, Jin S, Kim JH. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01483-y] [Reference Citation Analysis]
49 Lingli X, Wenfang X. Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review. Life Sci 2022;:120543. [PMID: 35421452 DOI: 10.1016/j.lfs.2022.120543] [Reference Citation Analysis]
50 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol 2022;59:519-33. [PMID: 34988690 DOI: 10.1007/s00592-021-01830-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Mo M, Huang Z, Liang Y, Liao Y, Xia N. The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Dig Liver Dis 2022;54:461-8. [PMID: 34507895 DOI: 10.1016/j.dld.2021.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Martínez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ, Fernández-García JC. Obesity-related glomerulopathy: Current approaches and future perspectives. Obes Rev 2022;:e13450. [PMID: 35362662 DOI: 10.1111/obr.13450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
54 Sun L, Deng C, Gu Y, He Y, Yang L, Shi J. Effects of Dapagliflozin in Patients with Nonalcoholic Fatty Liver Disease:A Systematic Review and Meta-Analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2022;:101876. [PMID: 35321843 DOI: 10.1016/j.clinre.2022.101876] [Reference Citation Analysis]
55 Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci 2022;23:3107. [PMID: 35328527 DOI: 10.3390/ijms23063107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
56 Koo BK, Lim S. Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch13] [Reference Citation Analysis]
57 Yen FS, Hsu CC, Wei JC, Hou MC, Hwu CM. Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Front Med (Lausanne) 2022;9:839456. [PMID: 35252271 DOI: 10.3389/fmed.2022.839456] [Reference Citation Analysis]
58 Čertíková Chábová V, Zakiyanov O. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes. Int J Mol Sci 2022;23:2812. [PMID: 35269954 DOI: 10.3390/ijms23052812] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
59 Kim J, Kwon HS. Not Control but Conquest: Strategies for the Remission of Type 2 Diabetes Mellitus. Diabetes Metab J 2022;46:165-80. [PMID: 35385632 DOI: 10.4093/dmj.2021.0377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Kuchay MS, Misra A. Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. Diabetes Metab Syndr 2022;16:102446. [PMID: 35259705 DOI: 10.1016/j.dsx.2022.102446] [Reference Citation Analysis]
61 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Aragón-Herrera A, Otero-Santiago M, Anido-Varela L, Moraña-Fernández S, Campos-Toimil M, García-Caballero T, Barral L, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González-Juanatey JR, Feijóo-Bandín S, Lago F. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile. Front Pharmacol 2022;13:827033. [PMID: 35185578 DOI: 10.3389/fphar.2022.827033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Zhang Q, Zhang L, Liu K, Shang H, Ruan J, Yu Z, Meng S, Liang F, Wang T, Zhang H, Peng W, Wang Y, Chen J, Xiao T, Wang B. A Network Pharmacology Study on the Active Components and Targets of the Radix Ginseng and Radix Bupleuri Herb Pair for Treating Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2022;2022:1638740. [PMID: 35178098 DOI: 10.1155/2022/1638740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2022;54:170-82. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
65 Cariou B. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. Diabetes Obes Metab 2022;24 Suppl 2:15-27. [PMID: 35014161 DOI: 10.1111/dom.14651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Goya T, Imoto K, Tashiro S, Aoyagi T, Takahashi M, Kurokawa M, Suzuki H, Tanaka M, Kato M, Kohjima M, Ogawa Y. The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease. Gastroenterology Insights 2022;13:20-6. [DOI: 10.3390/gastroent13010003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
67 Lee MH, Neeland IJ, de Albuquerque Rocha N, Hughes C, Malloy CR, Jin ES. A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat. Metabol Open 2022;13:100161. [PMID: 35024596 DOI: 10.1016/j.metop.2021.100161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
68 Ma Y, Kan C, Qiu H, Liu Y, Hou N, Han F, Shi J, Sun X. Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease. Front Pharmacol 2021;12:793586. [PMID: 34992540 DOI: 10.3389/fphar.2021.793586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
69 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
70 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Puri P, Kotwal N. An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. J Clin Exp Hepatol 2022;12:560-74. [PMID: 35535116 DOI: 10.1016/j.jceh.2021.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Apostolopoulou M, Roden M. Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_20] [Reference Citation Analysis]
73 Kedyk A, Kutsyn O. Metabolic effects of empagliflozine. DOMS 2022. [DOI: 10.57105/2415-7252-2022-5-04] [Reference Citation Analysis]
74 Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [DOI: 10.4254/wjh.v13.i12.1991] [Reference Citation Analysis]
75 Drożdż K, Nabrdalik K, Hajzler W, Kwiendacz H, Gumprecht J, Lip GYH. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota. Nutrients 2021;14:103. [PMID: 35010976 DOI: 10.3390/nu14010103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
76 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Martianova MV, Laevskaya MY, Meltonian AR, Bregovskiy VB, Babenko AY. Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-82-90] [Reference Citation Analysis]
79 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO). Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2021. [PMID: 34914079 DOI: 10.1007/s40519-021-01287-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets 2021;:1-11. [PMID: 34904923 DOI: 10.1080/14728222.2021.2018418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Sciacqua A, Succurro E, Armentaro G, Miceli S, Pastori D, Rengo G, Sesti G. Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Fail Rev 2021. [PMID: 34859336 DOI: 10.1007/s10741-021-10182-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, Zelber-Sagi S, Hallsworth K, Busetto L, Frühbeck G, Dicker D, Woodward E, Korenjak M, Willemse J, Koek GH, Vinker S, Ungan M, Mendive JM, Lionis C. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep 2021;3:100322. [PMID: 34693236 DOI: 10.1016/j.jhepr.2021.100322] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
83 Das US, Paul A, Banerjee S. SGLT2 inhibitors in heart failure with reduced ejection fraction. Egypt Heart J 2021;73:93. [PMID: 34693498 DOI: 10.1186/s43044-021-00218-w] [Reference Citation Analysis]
84 Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract 2021:S1530-891X(21)01244-1. [PMID: 34606980 DOI: 10.1016/j.eprac.2021.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
85 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
86 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Sato M, Tamura Y, Kaga H, Yamasaki N, Kiya M, Kadowaki S, Sugimoto D, Funayama T, Someya Y, Kakehi S, Nojiri S, Satoh H, Kawamori R, Watada H. Short-Term SGLT2 Inhibitor Administration Does Not Alter Systemic Insulin Clearance in Type 2 Diabetes. Biomedicines 2021;9:1154. [PMID: 34572340 DOI: 10.3390/biomedicines9091154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Pokharel A, Kc S, Thapa P, Karki N, Shrestha R, Jaishi B, Paudel MS. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. Cureus 2021;13:e16687. [PMID: 34466320 DOI: 10.7759/cureus.16687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
89 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 64.5] [Reference Citation Analysis]
90 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
91 Ge M, Merscher S, Fornoni A. Use of Lipid-Modifying Agents for the Treatment of Glomerular Diseases. J Pers Med 2021;11:820. [PMID: 34442464 DOI: 10.3390/jpm11080820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Saffo S, Kaplan DE, Mahmud N, Serper M, John BV, Ross JS, Taddei T. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obes Metab 2021;23:2402-8. [PMID: 34227216 DOI: 10.1111/dom.14488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Smati S, Canivet CM, Boursier J, Cariou B. Anti-diabetic drugs and NASH: from current options to promising perspectives. Expert Opin Investig Drugs 2021;30:813-25. [PMID: 34214406 DOI: 10.1080/13543784.2021.1951701] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
94 Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021;398:262-76. [PMID: 34216571 DOI: 10.1016/S0140-6736(21)00536-5] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 37.0] [Reference Citation Analysis]
95 Abdallah MS, Eldeen AH, Tantawy SS, Mostafa TM. The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial. Eur J Pharmacol 2021;906:174295. [PMID: 34214585 DOI: 10.1016/j.ejphar.2021.174295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Yoneda M, Honda Y, Ogawa Y, Kessoku T, Kobayashi T, Imajo K, Ozaki A, Nogami A, Taguri M, Yamanaka T, Kirikoshi H, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.BMJ Open Diabetes Res Care. 2021;9. [PMID: 33593749 DOI: 10.1136/bmjdrc-2020-001990] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
97 Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41. [PMID: 31629366 DOI: 10.1210/endrev/bnz009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 80] [Article Influence: 35.0] [Reference Citation Analysis]
98 Shao SC, Kuo LT, Chien RN, Hung MJ, Lai EC. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care 2020;8:e001956. [PMID: 33268450 DOI: 10.1136/bmjdrc-2020-001956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
99 Makri ES, Goulas A, Polyzos SA. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 2021;907:174272. [PMID: 34147478 DOI: 10.1016/j.ejphar.2021.174272] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Wei Q, Xu X, Guo L, Li J, Li L. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Front Endocrinol (Lausanne) 2021;12:635556. [PMID: 34220701 DOI: 10.3389/fendo.2021.635556] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
101 Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95. [PMID: 34131333 DOI: 10.1038/s41574-021-00507-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 54] [Article Influence: 23.5] [Reference Citation Analysis]
102 Sheu WHH, Chan SP, Matawaran BJ, Deerochanawong C, Mithal A, Chan J, Suastika K, Khoo CM, Nguyen HM, Linong J, Luk A, Yoon KH. Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations. Diabetes Metab J 2020;44:11-32. [PMID: 32097996 DOI: 10.4093/dmj.2019.0208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
103 Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int J Mol Sci 2021;22:6332. [PMID: 34199317 DOI: 10.3390/ijms22126332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
104 Euh W, Lim S, Kim JW. Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:613389. [PMID: 34177796 DOI: 10.3389/fendo.2021.613389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Bagriy AE, Zubov AD, Khomenko MV, Mikhailichenko ES, Pylaeva EA, Khaustova NA, Bryukhovetskaya EV. Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2021;31:14-26. [DOI: 10.22416/1382-4376-2021-31-2-14-26] [Reference Citation Analysis]
106 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
107 Song T, Chen S, Zhao H, Wang F, Song H, Tian D, Yang Q, Qi L. Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease. Hepatol Res 2021;51:641-51. [PMID: 33847462 DOI: 10.1111/hepr.13645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
108 Lee KW, Devaraj NK, Ching SM, Veettil SK, Hoo FK, Deuraseh I, Soo MJ. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. Oman Med J 2021;36:e273. [PMID: 34239714 DOI: 10.5001/omj.2021.62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
109 Aso Y, Sagara M, Niitani T, Kato K, Iijima T, Tomaru T, Jojima T, Usui I. Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease. J Investig Med 2021;69:1324-9. [PMID: 34016738 DOI: 10.1136/jim-2020-001621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
111 Das C, Tripathy D, Swain S, Sudhakaran N, Uthansingh K, Mallick P, Pati GK. Effect of Dapagliflozin on Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Single-Center Survey. Cureus 2021;13:e14974. [PMID: 34123670 DOI: 10.7759/cureus.14974] [Reference Citation Analysis]
112 Garg K, Brackett S, Hirsch IB, Garg SK. NAFLD/NASH and Diabetes. Diabetes Technol Ther 2020;22:S174-86. [PMID: 32069155 DOI: 10.1089/dia.2020.2513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
113 Hiroshi B. Recent Perspectives for Combined Status of Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). EJBMR 2021. [DOI: 10.33805/2690-2613.118] [Reference Citation Analysis]
114 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Gastaldelli A, Stefan N, Häring HU. Liver-targeting drugs and their effect on blood glucose and hepatic lipids. Diabetologia 2021;64:1461-79. [PMID: 33877366 DOI: 10.1007/s00125-021-05442-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
116 Hoong CWS, Chua MWJ. SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases. Endocrinology 2021;162:bqab079. [PMID: 33857309 DOI: 10.1210/endocr/bqab079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
117 Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne) 2021;8:615978. [PMID: 33937277 DOI: 10.3389/fmed.2021.615978] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 15.0] [Reference Citation Analysis]
118 Yoshino K, Hosooka T, Shinohara M, Aoki C, Hosokawa Y, Imamori M, Ogawa W. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2. Biochem Biophys Res Commun 2021;557:62-8. [PMID: 33862461 DOI: 10.1016/j.bbrc.2021.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
119 Papaetis GS. Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state. Arch Med Sci Atheroscler Dis 2021;6:e57-78. [PMID: 34027215 DOI: 10.5114/amsad.2021.105314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Zhang E, Zhao Y, Hu H. Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus. Hepatol Commun 2021;5:736-48. [PMID: 34027265 DOI: 10.1002/hep4.1611] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
121 Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int 2021;41:731-42. [PMID: 33497019 DOI: 10.1111/liv.14799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
122 Chrysavgis L, Papatheodoridi AM, Chatzigeorgiou A, Cholongitas E. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:893-909. [PMID: 33439540 DOI: 10.1111/jgh.15202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
123 Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab 2021;12:20420188211000243. [PMID: 33815743 DOI: 10.1177/20420188211000243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
124 Caussy C, Aubin A, Loomba R. The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Curr Diab Rep 2021;21:15. [PMID: 33742318 DOI: 10.1007/s11892-021-01383-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
125 Meng Z, Liu X, Li T, Fang T, Cheng Y, Han L, Sun B, Chen L. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol 2021;94:107492. [PMID: 33647823 DOI: 10.1016/j.intimp.2021.107492] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
126 Seino H. Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial. Diabetes Ther 2021;12:863-77. [PMID: 33594581 DOI: 10.1007/s13300-021-01014-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Curr Hepatol Rep. 2020;19:315-326. [PMID: 33585157 DOI: 10.1007/s11901-020-00530-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Reza Babaei M, Zamani F, Ajdarkosh H, Khoonsari M, Fallah AE, Khamseh ME. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Diabetes Ther. 2021;12:843-861. [PMID: 33586120 DOI: 10.1007/s13300-021-01011-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
129 Wong C, Yaow CYL, Ng CH, Chin YH, Low YF, Lim AYL, Muthiah MD, Khoo CM. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis. Front Endocrinol (Lausanne) 2020;11:609135. [PMID: 33643221 DOI: 10.3389/fendo.2020.609135] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
130 Harreiter J, Just I, Leutner M, Bastian M, Brath H, Schelkshorn C, Klepochova R, Krššák M, Kautzky-Willer A. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab 2021;23:1129-39. [PMID: 33464703 DOI: 10.1111/dom.14319] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
131 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
132 Sinha B, Datta D, Ghosal S. Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes. JGH Open 2021;5:219-27. [PMID: 33553659 DOI: 10.1002/jgh3.12473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
133 Horii T, Kozawa J, Fujita S, Hosokawa Y, Kimura T, Fujita Y, Tokunaga A, Fukui K, Shimomura I. Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium-glucose cotransporter 2 inhibitors: a retrospective study. Obes Sci Pract 2021;7:346-52. [PMID: 34123402 DOI: 10.1002/osp4.482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Dwinata M, Putera DD, Hasan I, Raharjo M. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clin Exp Hepatol 2020;6:339-46. [PMID: 33511282 DOI: 10.5114/ceh.2020.102173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
135 Ishizuka T, Tokuyama Y, Horie A, Kanatsuka A. Improved insulin sensitivity with sodium-glucose cotransporter 2 inhibitor treatment in a patient with slowly progressive type 1 diabetes mellitus with metabolic syndrome: a case report. Diabetol Int 2021;12:130-4. [PMID: 33479589 DOI: 10.1007/s13340-020-00448-4] [Reference Citation Analysis]
136 Li T, Fang T, Xu L, Liu X, Li X, Xue M, Yu X, Sun B, Chen L. Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro. Front Pharmacol 2020;11:622153. [PMID: 33551821 DOI: 10.3389/fphar.2020.622153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
137 Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Adv Exp Med Biol 2021;1307:213-30. [PMID: 32006266 DOI: 10.1007/5584_2020_479] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
138 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
139 Fu ZD, Cai XL, Yang WJ, Zhao MM, Li R, Li YF. Novel glucose-lowering drugs for non-alcoholic fatty liver disease. World J Diabetes 2021; 12(1): 84-97 [PMID: 33520110 DOI: 10.4239/wjd.v12.i1.84] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
140 Mishina EE, Mayorov AY, Bogomolov PO, Liusina EO, Bueverov AO. Association of insulin resistance and non-alcoholic fatty liver disease. Diabetes mellitus 2021;23:412-423. [DOI: 10.14341/dm12234] [Reference Citation Analysis]
141 Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. J Clin Endocrinol Metab 2020;105:dgaa057. [PMID: 32044999 DOI: 10.1210/clinem/dgaa057] [Cited by in Crossref: 43] [Cited by in F6Publishing: 56] [Article Influence: 21.5] [Reference Citation Analysis]
142 Santoro N, Goldberg-gel R, Caprio S. Nonalcoholic Fatty Liver Disease (NAFLD) Association with Pediatric Diabetes. Contemporary Endocrinology 2021. [DOI: 10.1007/978-3-030-64133-7_17] [Reference Citation Analysis]
143 Yoo JH, Kim JH. SGLT2 Inhibitors. Stroke Revisited 2021. [DOI: 10.1007/978-981-16-5123-6_13] [Reference Citation Analysis]
144 Kumar J, Memon RS, Shahid I, Rizwan T, Zaman M, Menezes RG, Kumar S, Siddiqi TJ, Usman MS. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. Dig Liver Dis 2021;53:44-51. [PMID: 32912770 DOI: 10.1016/j.dld.2020.08.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
145 Manka PP, Kaya E, Canbay A, Syn WK. A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021;66:3676-88. [PMID: 34410573 DOI: 10.1007/s10620-021-07206-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites 2020;11:22. [PMID: 33396949 DOI: 10.3390/metabo11010022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
147 Tobita H, Yazaki T, Kataoka M, Kotani S, Oka A, Mishiro T, Oshima N, Kawashima K, Ishimura N, Naora K, Sato S, Ishihara S. Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. J Clin Biochem Nutr 2021;68:173-80. [PMID: 33879970 DOI: 10.3164/jcbn.20-129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
148 Kalogirou MS, Patoulias D, Haidich AB, Akriviadis E, Sinakos E. Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol 2021;45:101568. [PMID: 33309563 DOI: 10.1016/j.clinre.2020.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
149 Gupta R, Alcantara R, Popli T, Mahajan S, Tariq U, Dusaj RS, Malik AH. Myopathy Associated With Statins and SGLT2 - A Review of Literature. Curr Probl Cardiol 2021;46:100765. [PMID: 33385749 DOI: 10.1016/j.cpcardiol.2020.100765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
150 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
151 Saffo S, Garcia-Tsao G, Taddei T. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension. J Diabetes 2021;13:265-9. [PMID: 33210815 DOI: 10.1111/1753-0407.13136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
152 Gameil MA, Abdelgawad MS, Bahgat MH, Elsebaie AH, Marzouk RE. Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus. Egypt J Intern Med 2020;32:12. [DOI: 10.1186/s43162-020-00013-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Miyazaki R, Miyagi K, Yoshida M. Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin. Ren Replace Ther 2020;6:55. [DOI: 10.1186/s41100-020-00303-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Stojsavljevic-Shapeski S, Duvnjak M, Virovic-Jukic L, Hrabar D, Smircic Duvnjak L. New Drugs on the Block-Emerging Treatments for Nonalcoholic Steatohepatitis. J Clin Transl Hepatol 2021;9:51-9. [PMID: 33604255 DOI: 10.14218/JCTH.2020.00057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Simental-Mendía M, Sánchez-García A, Rodríguez-Ramírez M, Simental-Mendía LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2021;163:105319. [PMID: 33246172 DOI: 10.1016/j.phrs.2020.105319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
156 Bae J, Huh JH, Lee M, Lee YH, Lee BW. Glycaemic control with add-on thiazolidinedione or a sodium-glucose co-transporter-2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24-week, randomized controlled trial. Diabetes Obes Metab 2021;23:609-18. [PMID: 33217092 DOI: 10.1111/dom.14259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Kuchay MS, Choudhary NS, Mishra SK, Misra A. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Diabetes Metab Syndr 2020;14:2233-9. [PMID: 33336648 DOI: 10.1016/j.dsx.2020.11.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
158 Taheri H, Malek M, Ismail-Beigi F, Zamani F, Sohrabi M, Reza Babaei M, Khamseh ME. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv Ther 2020;37:4697-708. [PMID: 32975679 DOI: 10.1007/s12325-020-01498-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
159 Mantovani A, Byrne C, Scorletti E, Mantzoros C, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes & Metabolism 2020;46:427-41. [DOI: 10.1016/j.diabet.2019.12.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 16.7] [Reference Citation Analysis]
160 Bossi AC, Forloni F, Colombelli PL. A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes Ther 2020;11:3007-9. [PMID: 33052537 DOI: 10.1007/s13300-020-00943-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
162 Burra P, Becchetti C, Germani G. NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Rep 2020;2:100192. [PMID: 33163950 DOI: 10.1016/j.jhepr.2020.100192] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
163 Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
164 Arab JP, Dirchwolf M, Álvares-da-Silva MR, Barrera F, Benítez C, Castellanos-Fernandez M, Castro-Narro G, Chavez-Tapia N, Chiodi D, Cotrim H, Cusi K, de Oliveira CPMS, Díaz J, Fassio E, Gerona S, Girala M, Hernandez N, Marciano S, Masson W, Méndez-Sánchez N, Leite N, Lozano A, Padilla M, Panduro A, Paraná R, Parise E, Perez M, Poniachik J, Restrepo JC, Ruf A, Silva M, Tagle M, Tapias M, Torres K, Vilar-Gomez E, Costa Gil JE, Gadano A, Arrese M. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease. Ann Hepatol 2020;19:674-90. [PMID: 33031970 DOI: 10.1016/j.aohep.2020.09.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
165 Hanif H, Khan MM, Ali MJ, Shah PA, Satiya J, Lau DTY, Aslam A. A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Microorganisms 2020;8:E1526. [PMID: 33020450 DOI: 10.3390/microorganisms8101526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
166 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
167 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 176] [Cited by in F6Publishing: 199] [Article Influence: 58.7] [Reference Citation Analysis]
168 Polyzos SA, Kang ES, Boutari C, Rhee E, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020;111:154203. [DOI: 10.1016/j.metabol.2020.154203] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 21.7] [Reference Citation Analysis]
169 Marton A, Kaneko T, Kovalik JP, Yasui A, Nishiyama A, Kitada K, Titze J. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 2021;17:65-77. [PMID: 33005037 DOI: 10.1038/s41581-020-00350-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
170 Chung W, Promrat K, Wands J. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases. World J Hepatol 2020; 12(9): 533-557 [PMID: 33033564 DOI: 10.4254/wjh.v12.i9.533] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
171 Kajitani N, Takahashi J, Honda H, Hamahara J, Ando S. Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer. Intern Med 2020;59:2281-5. [PMID: 32522924 DOI: 10.2169/internalmedicine.4653-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Abdelhamid AM, Elsheakh AR, Abdelaziz RR, Suddek GM. Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice. Life Sciences 2020;256:117908. [DOI: 10.1016/j.lfs.2020.117908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
173 Aggarwal P, Singh T, Alkhouri N. Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root. Curr Hepatology Rep 2020;19:302-314. [DOI: 10.1007/s11901-020-00533-x] [Reference Citation Analysis]
174 Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 2020;63:2434-45. [PMID: 32865597 DOI: 10.1007/s00125-020-05265-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 18.7] [Reference Citation Analysis]
175 Attia SL, Softic S, Mouzaki M. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021;14:11-9. [PMID: 32583961 DOI: 10.1111/cts.12839] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
176 Liu ST, Su KQ, Zhang LH, Liu MH, Zhao WX. Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e21568. [PMID: 32769900 DOI: 10.1097/MD.0000000000021568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Cernea S, Raz I. NAFLD in type 2 diabetes mellitus: Still many challenging questions. Diabetes Metab Res Rev 2021;37. [DOI: 10.1002/dmrr.3386] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
178 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
179 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
180 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
181 Seferović PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T, Bauersachs J, Anker SD, Ray R, Çavuşoğlu Y, Polovina M, Metra M, Ambrosio G, Prasad K, Seferović J, Jhund PS, Dattilo G, Čelutkiene J, Piepoli M, Moura B, Chioncel O, Ben Gal T, Heymans S, Boer RA, Jaarsma T, Hill L, Lopatin Y, Lyon AR, Ponikowski P, Lainščak M, Jankowska E, Mueller C, Cosentino F, Lund L, Filippatos GS, Ruschitzka F, Coats AJ, Rosano GM. Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020;22:1495-503. [DOI: 10.1002/ejhf.1954] [Cited by in Crossref: 82] [Cited by in F6Publishing: 89] [Article Influence: 27.3] [Reference Citation Analysis]
182 Connelly MA, Velez Rivera J, Guyton JR, Siddiqui MS, Sanyal AJ. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2020;52:619-36. [PMID: 32638417 DOI: 10.1111/apt.15935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
183 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
184 Gunhan HG, Imre E, Erel P, Ustay O. EMPAGLIFLOZIN IS MORE EFFECTIVE IN REDUCING MICROALBUMINURIA AND ALT LEVELS COMPARED WITH DAPAGLIFLOZIN: REAL LIFE EXPERIENCE. Acta Endocrinol (Buchar) 2020;16:59-67. [PMID: 32685040 DOI: 10.4183/aeb.2020.59] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
185 Gorgojo-Martínez JJ, Gargallo-Fernández MA, Galdón Sanz-Pastor A, Antón-Bravo T, Brito-Sanfiel M, Wong-Cruz J. Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study. J Clin Med 2020;9:E2275. [PMID: 32708943 DOI: 10.3390/jcm9072275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
186 Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020;17:761-72. [PMID: 32665641 DOI: 10.1038/s41569-020-0406-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 195] [Article Influence: 59.0] [Reference Citation Analysis]
187 Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetol Metab Syndr. 2020;12:60. [PMID: 32684985 DOI: 10.1186/s13098-020-00570-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 137] [Article Influence: 42.3] [Reference Citation Analysis]
188 Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med 2020;37:1793-806. [PMID: 32619031 DOI: 10.1111/dme.14356] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
189 Sumida Y, Yoneda M, Toyoda H, Yasuda S, Tada T, Hayashi H, Nishigaki Y, Suzuki Y, Naiki T, Morishita A, Tobita H, Sato S, Kawabe N, Fukunishi S, Ikegami T, Kessoku T, Ogawa Y, Honda Y, Nakahara T, Munekage K, Ochi T, Sawada K, Takahashi A, Arai T, Kogiso T, Kimoto S, Tomita K, Notsumata K, Nonaka M, Kawata K, Takami T, Kumada T, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone? Int J Mol Sci 2020;21:E4939. [PMID: 32668632 DOI: 10.3390/ijms21144939] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
190 Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther 2020;11:1849-60. [PMID: 32648108 DOI: 10.1007/s13300-020-00867-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
191 Shin Y, Moon JH, Chin HJ, Ferrannini E, Lim S. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea. Endocrinol Metab (Seoul) 2020;35:329-38. [PMID: 32615717 DOI: 10.3803/EnM.2020.35.2.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
192 Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother 2021;55:65-79. [PMID: 32571083 DOI: 10.1177/1060028020935105] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
193 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
194 Bica C, Sandu C, Suceveanu AI, Sarbu E, Stoica RA, Gherghiceanu F, Bohiltea RE, Stefan SD, Stoian AP. Non-alcoholic fatty liver disease: A major challenge in type 2 diabetes mellitus (Review). Exp Ther Med 2020;20:2387-91. [PMID: 32765720 DOI: 10.3892/etm.2020.8882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
195 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
196 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
197 Zong Y, Yan J, Jin L, Xu B, He Z, Zhang R, Hu C, Jia W. Relationship between circulating miR-132 and non-alcoholic fatty liver disease in a Chinese population. Hereditas 2020;157:22. [PMID: 32443971 DOI: 10.1186/s41065-020-00136-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
198 Lee BW, Lee YH, Park CY, Rhee EJ, Lee WY, Kim NH, Choi KM, Park KG, Choi YK, Cha BS, Lee DH; Korean Diabetes Association (KDA) Fatty Liver Research Group. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J 2020;44:382-401. [PMID: 32431115 DOI: 10.4093/dmj.2020.0010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
199 Kim KS, Lee BW, Kim YJ, Lee DH, Cha BS, Park CY. Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment. Diabetes Metab J 2019;43:127-43. [PMID: 30993937 DOI: 10.4093/dmj.2019.0034] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
200 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 29.0] [Reference Citation Analysis]
201 Wu P, Liu Z, Jiang X, Fang H. An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes. CDT 2020;21:445-57. [DOI: 10.2174/1389450120666191031104653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
202 Xing B, Zhao Y, Dong B, Zhou Y, Lv W, Zhao W. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. J Diabetes Investig 2020;11:1238-47. [PMID: 32083798 DOI: 10.1111/jdi.13237] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
203 Lv Q, Le L, Xiang J, Jiang B, Chen S, Xiao P. Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats. Front Endocrinol (Lausanne) 2020;11:111. [PMID: 32256445 DOI: 10.3389/fendo.2020.00111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
204 Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, Imajo K, Takahashi H, Eguchi Y, Ono M, Nozaki Y, Hyogo H, Koseki M, Yoshida Y, Kawaguchi T, Kamada Y, Okanoue T, Nakajima A, Jsg-Nafld JSGON. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int J Mol Sci 2020;21:E1907. [PMID: 32168769 DOI: 10.3390/ijms21061907] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
205 Y S, M Y, K T, M K, H F, M Y, K I, H T, M O, Y N, H H, M K, Y Y, T K, Y K, Y E, T O, A N. Hepatoprotective Effect of SGLT2 Inhibitor on Nonalcoholic Fatty Liver Disease. Diab Res Open Access 2020;2:17-25. [DOI: 10.36502/2020/droa.6159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
206 Kalra S, Shetty KK, Nagarajan VB, Ved JK. Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. Diabetes Ther 2020;11:813-33. [PMID: 32130664 DOI: 10.1007/s13300-020-00789-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
207 Wattacheril J. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:141-9. [PMID: 32033760 DOI: 10.1016/j.gtc.2019.10.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
208 Chait A, den Hartigh LJ. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med. 2020;7:22. [PMID: 32158768 DOI: 10.3389/fcvm.2020.00022] [Cited by in Crossref: 293] [Cited by in F6Publishing: 314] [Article Influence: 97.7] [Reference Citation Analysis]
209 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
210 Garg SK, Brackett S, Reinicke T, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther 2020;22:S149-73. [PMID: 32069157 DOI: 10.1089/dia.2020.2512] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
211 Cusi K. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. Liver Int 2020;40 Suppl 1:82-8. [PMID: 32077613 DOI: 10.1111/liv.14350] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
212 Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 2020;65:623-31. [PMID: 30684076 DOI: 10.1007/s10620-019-5477-1] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 26.0] [Reference Citation Analysis]
213 Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem 2020;63:5031-73. [PMID: 31930920 DOI: 10.1021/acs.jmedchem.9b01701] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 14.7] [Reference Citation Analysis]
214 Bonora BM, Avogaro A, Fadini GP. Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes 2020;13:161-74. [PMID: 32021362 DOI: 10.2147/DMSO.S233538] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 23.0] [Reference Citation Analysis]
215 Takeshita Y, Kanamori T, Tanaka T, Kaikoi Y, Kita Y, Takata N, Iida N, Arai K, Yamashita T, Harada K, Gabata T, Nakamura H, Kaneko S, Takamura T. Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Diabetes Ther 2020;11:549-60. [PMID: 31956961 DOI: 10.1007/s13300-020-00762-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
216 Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y. Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway. Diabetologia 2020;63:577-87. [PMID: 31897526 DOI: 10.1007/s00125-019-05071-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
217 Solano-Urrusquieta A, Morales-González JA, Castro-Narro GE, Cerda-Reyes E, Flores-Rangel PD, Fierros-Oceguera R. NRF-2 and nonalcoholic fatty liver disease. Ann Hepatol 2020;19:458-65. [PMID: 31959521 DOI: 10.1016/j.aohep.2019.11.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
218 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
219 Qureshi K, Neuschwander-Tetri BA. The molecular basis for current targets of NASH therapies. Expert Opin Investig Drugs 2020;29:151-61. [PMID: 31847612 DOI: 10.1080/13543784.2020.1703949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
220 Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT. Evolution of NAFLD and Its Management. Nutr Clin Pract 2020;35:72-84. [PMID: 31840865 DOI: 10.1002/ncp.10449] [Cited by in Crossref: 73] [Cited by in F6Publishing: 83] [Article Influence: 18.3] [Reference Citation Analysis]
221 Yamakage H, Tanaka M, Inoue T, Odori S, Kusakabe T, Satoh-Asahara N. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial. J Diabetes Investig 2020;11:653-61. [PMID: 31721467 DOI: 10.1111/jdi.13179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
222 Kotsis V, Jordan J, Stabouli S, Antza C, Micic D, Jelaković B, Schlaich MP, Nilsson PM, Kreutz R, Mancia G, Tsioufis K, Grassi G. Cardiovascular, renal and liver protection with novel antidiabetic agents beyond blood glucose lowering in type 2 diabetes: consensus article from the European Society of Hypertension Working Group on Obesity, Diabetes and the High-risk Patient. J Hypertens 2020;38:377-86. [PMID: 31764586 DOI: 10.1097/HJH.0000000000002279] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
223 Ganguli S, DeLeeuw P, Satapathy SK. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Hepat Med 2019;11:159-78. [PMID: 31814783 DOI: 10.2147/HMER.S188991] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
224 Pennisi G, Celsa C, Spatola F, Dallio M, Federico A, Petta S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int J Environ Res Public Health 2019;16:E4334. [PMID: 31703268 DOI: 10.3390/ijerph16224334] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
225 Marjot T, Green CJ, Charlton CA, Cornfield T, Hazlehurst J, Moolla A, White S, Francis J, Neubauer S, Cobbold JF, Hodson L, Tomlinson JW. Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. JGH Open 2020;4:433-40. [PMID: 32514450 DOI: 10.1002/jgh3.12274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
226 Yanai H, Hakoshima M, Katsuyama H. The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors. J Clin Med Res 2019;11:769-72. [PMID: 31803320 DOI: 10.14740/jocmr4019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
227 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
228 Shao SC, Chang KC, Chien RN, Lin SJ, Hung MJ, Chan YY, Kao Yang YH, Lai EC. Effects of sodium-glucose co-transporter-2 inhibitors on serum alanine aminotransferase levels in people with type 2 diabetes: A multi-institutional cohort study. Diabetes Obes Metab 2020;22:128-34. [PMID: 31486260 DOI: 10.1111/dom.13875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
229 Lajara R. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgrad Med 2019;131:555-65. [PMID: 31580737 DOI: 10.1080/00325481.2019.1670017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
230 Handelsman Y. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther 2019;36:2567-86. [PMID: 31444707 DOI: 10.1007/s12325-019-01054-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
231 Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, Wang W, Feng S, Zhong B. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol 2019;12:1756284819879047. [PMID: 31632457 DOI: 10.1177/1756284819879047] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
232 Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig 2019;39:631-41. [PMID: 30993553 DOI: 10.1007/s40261-019-00785-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
233 Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, González-Nava V, Contreras-Garza BM, Díaz González-Colmenero A, Rodríguez-Tamez G, Barrera-Flores FJ, Farrell AM, Montori VM, Rodriguez-Gutierrez R. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest 2020;43:289-304. [PMID: 31489568 DOI: 10.1007/s40618-019-01103-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
234 Omori K, Nakamura A, Miyoshi H, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Takagi R, Hatanaka KC, Terauchi Y, Atsumi T. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. Metabolism 2019;98:27-36. [DOI: 10.1016/j.metabol.2019.06.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
235 Patel DK, Strong J. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther 2019;10:1771-92. [PMID: 31456166 DOI: 10.1007/s13300-019-00686-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
236 Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol 2019;498:110539. [PMID: 31419466 DOI: 10.1016/j.mce.2019.110539] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
237 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
238 Khan RS, Bril F, Cusi K, Newsome PN. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology 2019;70:711-24. [PMID: 30556145 DOI: 10.1002/hep.30429] [Cited by in Crossref: 97] [Cited by in F6Publishing: 122] [Article Influence: 24.3] [Reference Citation Analysis]
239 Kontana A, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2019; 25(28): 3664-3668 [PMID: 31391764 DOI: 10.3748/wjg.v25.i28.3664] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
240 Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. World J Hepatol 2019; 11(7): 562-573 [PMID: 31388398 DOI: 10.4254/wjh.v11.i7.562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
241 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 148] [Article Influence: 34.8] [Reference Citation Analysis]
242 Katsiki N, Perakakis N, Mantzoros C. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus? Metabolism 2019;98:iii-ix. [PMID: 31301336 DOI: 10.1016/j.metabol.2019.07.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
243 Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, Brandt N, Frandsen M, Chabanova E, Dela F, Faber J, Kistorp C. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). Diabetes Obes Metab 2019;21:2305-14. [PMID: 31183945 DOI: 10.1111/dom.13809] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
244 Gharaibeh NE, Rahhal MN, Rahimi L, Ismail-Beigi F. SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. Diabetes Metab Syndr Obes 2019;12:1001-12. [PMID: 31308716 DOI: 10.2147/DMSO.S212715] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
245 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 18.8] [Reference Citation Analysis]
246 Obmann VC, Mertineit N, Marx C, Berzigotti A, Ebner L, Heverhagen JT, Christe A, Huber AT. Liver MR relaxometry at 3T - segmental normal T1 and T2* values in patients without focal or diffuse liver disease and in patients with increased liver fat and elevated liver stiffness. Sci Rep 2019;9:8106. [PMID: 31147588 DOI: 10.1038/s41598-019-44377-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
247 M. Ahmad M, Addin Brema I, H. Almalki M. SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus. Type 2 Diabetes [Working Title] 2019. [DOI: 10.5772/intechopen.84152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
248 Katsiki N, Dimitriadis G, Mikhailidis DP. Perirenal Adiposity and Other Excessive Intra- and Peri-Organ Fat Depots: What Is the Connection? Angiology 2018;70:581-3. [DOI: 10.1177/0003319719848204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
249 Francque S, Vonghia L. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. Adv Ther 2019;36:1052-74. [PMID: 30888594 DOI: 10.1007/s12325-019-00898-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 11.0] [Reference Citation Analysis]
250 Kim JW, Lee YJ, You YH, Moon MK, Yoon KH, Ahn YB, Ko SH. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem 2019;120:8534-46. [PMID: 30474134 DOI: 10.1002/jcb.28141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
251 Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, Holman R, Pavlides M, Ryan JD, Tomlinson JW, Cobbold JF. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol 2019;10:337-46. [PMID: 31682643 DOI: 10.1136/flgastro-2018-101155] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
252 Lee SJ, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:523-30. [PMID: 31018719 DOI: 10.1080/17474124.2019.1608820] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
253 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
254 Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2019;8:247-67. [PMID: 31004828 DOI: 10.1016/j.jcmgh.2019.04.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 17.3] [Reference Citation Analysis]
255 Nakamura I, Maegawa H, Tobe K, Uno S. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study. Adv Ther 2019;36:923-49. [PMID: 30767112 DOI: 10.1007/s12325-019-0895-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
256 Jung CH, Mok JO. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. J Obes Metab Syndr 2019;28:18-29. [PMID: 31089576 DOI: 10.7570/jomes.2019.28.1.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
257 Toledo Frías P, Campuzano Ruiz R, Alarcón Duque JA, Berenguel Senén A, Fernández Olmo MR, Abeytua Jiménez M. Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca. REC: CardioClinics 2019;54:44-50. [DOI: 10.1016/j.rccl.2019.01.007] [Reference Citation Analysis]
258 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 350] [Cited by in F6Publishing: 382] [Article Influence: 87.5] [Reference Citation Analysis]
259 Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. World J Diabetes 2019; 10(2): 114-132 [PMID: 30788048 DOI: 10.4239/wjd.v10.i2.114] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 42] [Article Influence: 10.5] [Reference Citation Analysis]
260 Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213-223. [PMID: 30708071 DOI: 10.1016/j.diabet.2019.01.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 16.8] [Reference Citation Analysis]
261 Grancini V, Resi V, Palmieri E, Pugliese G, Orsi E. Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacol Res. 2019;141:556-573. [PMID: 30690071 DOI: 10.1016/j.phrs.2019.01.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
262 Inoue M, Hayashi A, Taguchi T, Arai R, Sasaki S, Takano K, Inoue Y, Shichiri M. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 2019;10:1004-11. [PMID: 30461221 DOI: 10.1111/jdi.12980] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
263 Bedi O, Aggarwal S, Trehanpati N, Ramakrishna G, Krishan P. Molecular and Pathological Events Involved in the Pathogenesis of Diabetes-Associated Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:607-18. [PMID: 31695251 DOI: 10.1016/j.jceh.2018.10.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
264 Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, Osonoi T. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial). Hepatol Res 2019;49:64-71. [PMID: 30051943 DOI: 10.1111/hepr.13236] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 17.0] [Reference Citation Analysis]
265 Kothari S, Dhami-Shah H, Shah SR. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:723-30. [PMID: 31889754 DOI: 10.1016/j.jceh.2019.06.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
266 Ashraf H, Ahmad J. Cardiovascular outcome trials in type 2 diabetes: A critical analysis. Diabetes Metab Syndr 2019;13:300-5. [PMID: 30641716 DOI: 10.1016/j.dsx.2018.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Krentz AJ, Bedossa P. Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease 2019. [DOI: 10.1007/978-3-030-11748-1_10] [Reference Citation Analysis]
268 Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, Sunny NE, Kalavalapalli S, Pettus J, Ciaraldi TP, Mudaliar S, Henry RR. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019;21:812-821. [PMID: 30447037 DOI: 10.1111/dom.13584] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
269 Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab Syndr Obes 2018;11:835-43. [PMID: 30568471 DOI: 10.2147/DMSO.S184767] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
270 El Essawy B, Kandeel F. Pre, peri and posttransplant diabetes mellitus. Curr Opin Nephrol Hypertens 2019;28:47-57. [PMID: 30418189 DOI: 10.1097/MNH.0000000000000469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
271 Kahl S. Effizienz antidiabetischer Kombinationstherapien bei nichtalkoholischer Fettlebererkrankung und Typ‑2‑Diabetes. Diabetologe 2018;14:601-2. [DOI: 10.1007/s11428-018-0422-z] [Reference Citation Analysis]
272 Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel). 2018;11:121. [PMID: 30413050 DOI: 10.3390/ph11040121] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
273 Scheen AJ. Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Ann Transl Med. 2018;6:S68. [PMID: 30613643 DOI: 10.21037/atm.2018.10.39] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
274 Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou AE, Mantzoros CS. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019;92:170-92. [PMID: 30391259 DOI: 10.1016/j.metabol.2018.10.010] [Cited by in Crossref: 110] [Cited by in F6Publishing: 119] [Article Influence: 22.0] [Reference Citation Analysis]
275 Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H, Aso Y. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019;21:285-92. [DOI: 10.1111/dom.13520] [Cited by in Crossref: 150] [Cited by in F6Publishing: 157] [Article Influence: 30.0] [Reference Citation Analysis]
276 Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab 2018;44:457-64. [PMID: 30266577 DOI: 10.1016/j.diabet.2018.09.005] [Cited by in Crossref: 153] [Cited by in F6Publishing: 159] [Article Influence: 30.6] [Reference Citation Analysis]
277 Yabe D, Yasui A, Ji L, Lee MK, Ma RCW, Chang TJ, Okamura T, Zeller C, Kaspers S, Lee J, Kohler S, Seino Y. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials. J Diabetes Investig 2019;10:418-28. [PMID: 30099847 DOI: 10.1111/jdi.12910] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]